Pantoprazole Unifarma (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Unifarma, is a proton pump inhibitor presented as a solid oral dosage form for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders in adults and children.

GNH USA supplies Pantoprazole Unifarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Unifarma is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Erosive oesophagitis: heals mucosal breaks caused by chronic acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea or vomiting: occasional gastrointestinal upset. - Abdominal pain or flatulence: mild discomfort. - Constipation: infrequent but reported. - Dry mouth: transient sensation.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of kidney tissue. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Clostridioides difficile infection: associated with altered gut flora. - Osteoporosis‑related fractures: long‑term use may affect bone density. - Vitamin B12 deficiency: reduced absorption with chronic therapy.

Before initiating therapy, consider the following safety points: - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for reduced efficacy of drugs needing acidic pH. - Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections. - Evaluate bone health: long‑term use may impact calcium absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: markedly reduced antifungal absorption. - Atazanavir or nelfinavir: decreased antiviral exposure leading to therapeutic failure.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Digoxin: slight increase in serum levels; observe for toxicity signs. - Methotrexate (high dose): reduced renal clearance; check serum concentrations. - Mycophenolate mofetil: possible increase in exposure; adjust dose if needed.